세계의 세포 기반 분석 시장 보고서(2025년)
Cell Based Assays Global Market Report 2025
상품코드 : 1824519
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세포 기반 분석 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 13.1%를 나타내 481억 8,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 AI와 머신러닝의 통합, 규제 상황의 변화, 고 컨텐츠 스크리닝 수요, 질병 모델링의 진보, 정밀의료에 대한 주력에 기인한다고 생각됩니다. 예측 기간의 주요 동향에는 고처리량 스크리닝(HTA), 3d 세포 배양, 장기 온칩 기술, CRISPR/cas9 기술, 이미징 기술의 진보가 포함됩니다.

향후 5년간의 성장률 13.1%라고 하는 예측은 전회 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 장벽은 이스라엘과 캐나다에서 조달하는 3D 세포 배양 시스템과 고콘텐트 스크리닝 플랫폼의 비용을 상승시켜 전임상시험 일정을 늘리고 개발 비용에 50만 달러 이상을 늘려 미국의 의약품 개발을 방해할 것으로 예측됩니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

연구에서 세포 기반 분석의 사용은 증가하는 경향이 있으며, 최종 단계의 실패를 완화하기 위해 신약 개발에서보다 예측적인 세포 모델로의 이동이 필요합니다. 의약품을 효과적으로 상시하고 비용이 많이 드는 후기 단계에서의 실패를 경감하는 것이 제약 업계의 급무이며, 세포 기반 분석 기술 혁신의 중요한 추진력이 되고 있습니다. 임상시험약(IND)의 3상 임상시험 실패는 기업에 수억 달러에 이르는 많은 재무적 손실을 초래할 수 있습니다. 시그마의 보고서에 따르면, 제약회사의 투자이익률은 현재 후기 단계의 실패율을 고려하면 5%를 나타내 급감할 수 있으며, 이는 대부분의 기업에 대해 수용하기 어려운 수준입니다. 세포 기반 분석에서 높은 컨텐츠 시스템과 데이터 분석을 크게 강화하면 과학자들에게 세포 반응에 대한 더 많은 정보를 끌어낼 수 있으며, 약물에 대한 정보를 바탕으로 의사 결정을 돕고 세포 기반 분석 시장 성장을 더욱 촉진합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Cell-based assays are experimental tools designed for studying reactions occurring inside cells, allowing researchers to investigate various mechanisms and processes related to cellular function.

The main products and services associated with cell-based assays include consumables, instruments, services, and software. Consumables are items that are used up or depleted during their usage. Instruments commonly used in cell-based assays encompass microplates, microplate readers, high-throughput screening systems, and liquid handling systems. Various consumables essential for these assays include reagents and media, cells and cell lines, probes, and labels. Cell-based assays employ different technologies, such as automated handling, flow cytometry, label-free detection, high-throughput screening, among others. These assays find applications in drug discovery, basic research, ADME (Absorption, Distribution, Metabolism, and Excretion) studies, predictive toxicology, and other research purposes. End-users of cell-based assays include pharmaceutical and biotechnology companies, academic and government research institutes, contract research organizations (CROs), and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cell-based assays market research report is one of a series of new reports from The Business Research Company that provides cell-based assays market statistics, including cell-based assays industry global market size, regional shares, competitors with a cell-based assays market share, detailed cell-based assays market segments, market trends, and opportunities, and any further data you may need to thrive in the cell-based assays industry. This cell-based assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell based assays market size has grown strongly in recent years. It will grow from $27.07 billion in 2024 to $29.41 billion in 2025 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to emergence of HTS techniques, integration of automation, utilization of biomarker detection, adoption of microfluidics, introduction of gene editing tools.

The cell based assays market size is expected to see rapid growth in the next few years. It will grow to $48.18 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to integration of ai and machine learning, shift in regulatory landscape, demand for high-content screening, advancements in disease modeling, focus on precision medicine. Major trends in the forecast period include high-throughput screening (HTA), 3d cell cultures, organ-on-a-chip technology, CRISPR/cas9 technology, advancements in imaging techniques.

The forecast of 13.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. drug development by increasing the cost of 3D cell culture systems and high-content screening platforms sourced from Israel and Canada, thereby extending preclinical timelines and adding $500K+ to development costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The utilization of cell-based arrays in research is on the rise, necessitating a shift towards more predictive cellular models in drug discovery to mitigate last-stage failures. The pharmaceutical industry's imperative to effectively bring drugs to market and mitigate costly late-stage failures is a key driver in the innovation of cell-based assays. Failure in Phase III clinical trials of investigational new drugs (IND) can result in substantial financial losses, reaching several hundred million dollars for the company. Sigma's report indicates that the return on investment for pharmaceutical companies could plummet to 5% given the current rate of late-stage failures, an unacceptable level for most companies. Significant enhancements in high-content systems and data analysis in cell-based assays empower scientists to extract more information about cellular responses, aiding informed decision-making in drug discovery and further fueling the growth of the cell-based array market.

The rise in biologics sales is anticipated to significantly boost the cell-based assays market. Biologics, or biological products, are medicines derived from living organisms, encompassing a wide range of products such as vaccines, blood components, allergenics, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins. Cell-based assays play a crucial role in the biologics sector by evaluating functionality, potency, safety, and bio-similarity. For instance, in May 2022, the European Pharmaceutical Review (EPR), a UK-based non-governmental organization, projected that biologics would greatly exceed sales of innovative small molecules in the next five years, with an estimated $120 billion increase in sales by 2027. This trend reflects a significant shift in the pharmaceutical market toward biologic products. Therefore, the growth in biologics sales is driving the expansion of the cell-based assays market.

Major companies in the cell-based assays market are increasingly launching new platforms leveraging advanced technologies, such as cell-based phenotypic assay platforms, to enhance drug discovery efforts. These platforms evaluate cellular responses to compound treatments by integrating sophisticated imaging and analytical tools, often powered by artificial intelligence. For instance, in June 2024, Sphere Fluidics, a UK-based life sciences R&D company, introduced Cyto-Cellect PLUS. This user-friendly Fluorescence Resonance Energy Transfer (FRET) assay allows researchers to accurately measure IgG productivity with high sensitivity. Building on the original Cyto-Cellect Human IgGκ Detection Kit, the enhanced version also detects both IgG κ and λ light chains, expanding its utility. The assay is fully compatible with existing Cyto-Mine(R) functionality, enabling single-cell dispensing into 96-well and 384-well plates. Additionally, it meets relevant regulatory standards by being free of animal origins, facilitating its integration into current cell line development processes. Such innovations reflect the ongoing trend toward developing advanced, user-friendly solutions in the cell-based assays market, supporting the growing demand for effective drug discovery tools.

In May 2022, Cell Carta, a Canada-based provider of precision medicine laboratory services, acquired next-generation immune-MRM assays from Precision Assays for an undisclosed amount. This acquisition aims to strengthen Cell Carta's position in the proteomics vertical and enhance its service offerings in precision medicine laboratory services. Precision Assays, a US-based provider of next-generation targeted proteomics testing solutions, played a significant role in this strategic move.

Major companies operating in the cell based assays market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, GE HealthCare Technologies Inc., Corning Incorporated, Lonza Group Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Sigma-Aldrich Corporation, Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam plc, BioVision Inc., Promega Corporation, Cell Signaling Technology Inc., BioTek Instruments Inc., Enzo Life Sciences Inc., BioAgilytix Labs LLC, Cisbio International LLC, ProQinase GmbH, QGel SA, Biotium Inc., Selexis SA, Aurelia Bioscience Ltd., Creative Bioarray, Cell Biolabs Inc., Essen BioScience Ltd., Eurofins Scientific SE, DiscoveRx Corporation

North America was the largest region in the cell-based assays market in 2024. Western Europe was the second largest region in the global cell-based assays market share. The regions covered in the cell based assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cell based assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cell-based assay market consists of sales of reagents, cell lines, microplates, microplates, assay kits, probes, and labels. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell Based Assays Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell based assays market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cell based assays ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell based assays market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Cell Based Assays Market Characteristics

3. Cell Based Assays Market Trends And Strategies

4. Cell Based Assays Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cell Based Assays Growth Analysis And Strategic Analysis Framework

6. Cell Based Assays Market Segmentation

7. Cell Based Assays Market Regional And Country Analysis

8. Asia-Pacific Cell Based Assays Market

9. China Cell Based Assays Market

10. India Cell Based Assays Market

11. Japan Cell Based Assays Market

12. Australia Cell Based Assays Market

13. Indonesia Cell Based Assays Market

14. South Korea Cell Based Assays Market

15. Western Europe Cell Based Assays Market

16. UK Cell Based Assays Market

17. Germany Cell Based Assays Market

18. France Cell Based Assays Market

19. Italy Cell Based Assays Market

20. Spain Cell Based Assays Market

21. Eastern Europe Cell Based Assays Market

22. Russia Cell Based Assays Market

23. North America Cell Based Assays Market

24. USA Cell Based Assays Market

25. Canada Cell Based Assays Market

26. South America Cell Based Assays Market

27. Brazil Cell Based Assays Market

28. Middle East Cell Based Assays Market

29. Africa Cell Based Assays Market

30. Cell Based Assays Market Competitive Landscape And Company Profiles

31. Cell Based Assays Market Other Major And Innovative Companies

32. Global Cell Based Assays Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cell Based Assays Market

34. Recent Developments In The Cell Based Assays Market

35. Cell Based Assays Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기